This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
FDA Grants Priority Tag to Bayer's Oncology Drug for First-Line NSCLC
by Zacks Equity Research
BAYRY wins FDA priority review for sevabertinib in first-line HER2-mutant NSCLC, building momentum for the oral TKI.
BAYRYPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechs
ImmunityBio Secures Five U.S. Patents for Anktiva in Bladder Cancer
by Zacks Equity Research
IBRX secures five U.S. patents for Anktiva in bladder cancer, extending franchise protection through 2035 amid strong sales growth.
IMCRPositive Net Change IBRXPositive Net Change INDVPositive Net Change
biotechs medical
Bayer Gets FDA Priority Review for Asundexian NDA in Stroke Prevention
by Zacks Equity Research
BAYRY gains FDA Priority Review for asundexian NDA after phase III data showed a 26% cut in ischemic stroke risk without more major bleeding.
BAYRYPositive Net Change LQDAPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron's Late-Stage Melanoma Study Misses Primary Goal
by Zacks Equity Research
REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.
REGNPositive Net Change BMYPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
AZN, Daiichi's Enhertu Gets FDA Nod for Two New Breast Cancer Settings
by Zacks Equity Research
AstraZeneca and Daiichi win FDA approval for Enhertu in two new HER2-positive early breast cancer treatment settings.
AZNPositive Net Change RHHBYPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechs medical
Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
by Sundeep Ganoria
ABBV's neuroscience sales jump 26% in Q1, driven by Vraylar, migraine drugs and Botox as new therapies fuel growth.
BIIBNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals
AstraZeneca Gets FDA Nod for New Hypertension Drug Baxfendy
by Zacks Equity Research
AZN's Baxfendy wins FDA nod as the first aldosterone synthase inhibitor for adults with uncontrolled hypertension.
AZNPositive Net Change AMRNPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechs medical
Roche's Tecentriq Wins FDA Nod for Label Expansion in Bladder Cancer
by Zacks Equity Research
RHHBY wins FDA approval for Tecentriq label expansion as a ctDNA-guided adjuvant therapy for bladder cancer patients at high risk of recurrence.
RHHBYPositive Net Change AMRNPositive Net Change IMCRPositive Net Change INDVPositive Net Change
biotechnology biotechs immuno-therapy medical oncology-screening pharmaceuticals
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year
by Zacks Equity Research
KROS posts a wider Q1 loss as revenues fall due to the absence of license revenues. The company advances rinvatercept and elritercept studies.
AMRNPositive Net Change LQDAPositive Net Change KROSPositive Net Change INDVPositive Net Change
biotechs
How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?
by Sundeep Ganoria
ABBV's Q1 beat is powered by Skyrizi and Rinvoq, whose strong sales growth offset Humira declines and boosts 2026 guidance.
JNJNegative Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs earnings medical pharmaceuticals